Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121613 | 0.81 | CYP3A4 (0.48) | GLP1RNQO1PGK1NQO2GAA | |
| SCHEMBL121409 | 0.81 | NQO1 (0.46) | GLP1RNQO1PGK1GAAKDM4E | |
| SCHEMBL405486 | 0.81 | TDP1 (0.50) | GLP1RPGK1MMP1MMP2MMP3 | |
| SCHEMBL29558616 | 0.81 | TDP1 (0.50) | GLP1RPGK1MMP1MMP2MMP3 | |
| SCHEMBL7698365 | 0.79 | NQO2 (0.50) | NQO1NQO2GAAKDM4EALDH1A1 | |
| SCHEMBL1138685 | 0.78 | PIK3CG (0.55) | NQO1DYRK1AGAAKDM4EALDH1A1 | |
| SCHEMBL7237225 | 0.76 | GLP1R (0.48) | GLP1RNQO1PGK1MMP1MMP2 | |
| SCHEMBL4926286 | 0.76 | PGK1 (0.58) | NQO1PGK1ACHENQO2GAA | |
| SCHEMBL121118 | 0.75 | MAPT (0.67) | ACHENQO2GAAKDM4EALDH1A1 | |
| SCHEMBL1138054 | 0.74 | NQO2 (0.53) | NQO1NQO2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524436-B | 1-[(the alkoxyl group quinoxalinyl that 6,7-replaces) aminocarboxyl]-4-(mixing) aryl piperazine derivative | REXAHN PHARMACEUTICALS INC. (US) | 2015-09-23 | — | — | CN | disclosed |
| EP-2509983-B1 | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY | MERCK SHARP & DOHME (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8598173-B2 | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8314100-B2 | 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | disclosed |
| EP-1147094-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042026-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | HRAS, CDK4, KRAS | GLP1R 3532/4885NQO1 91/4885PGK1 438/4885 |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | HRAS, CDK4, KRAS | GLP1R 3250/4885NQO1 63/4885PGK1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.